Probing Oligomerized Conformations of Defensin in the Membrane

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2016 Dec 4

PMID 27914061

Citations 2

Authors

Wenxun Gan

Dina Schneidman

Ning Zhang

Buyong Ma

Ruth Nussinov

Affiliations

Soon will be listed here.

Abstract

Computational prediction and design of membrane protein-protein interactions facilitate biomedical engineering and biotechnological applications. Due to their antimicrobial activity, human defensins play an important role in the innate immune system. Human defensins are attractive pharmaceutical targets due to their small size, broad activity spectrum, reduced immunogenicity, and resistance to proteolysis. Protein engineering based modification of defensins can improve their pharmaceutical properties. Here we present an approach to computationally probe defensins' oligomerization states in the membrane. First, we develop a novel docking and rescoring algorithm. Then, on the basis of the 3D structure of Sapecin, an insect defensin, and a model of its antimicrobial ion-channel, we optimize the parameters of our empirical scoring function. Finally, we apply our docking program and scoring function to the hBD-2 (human β-defensin-2) molecule and obtain structures of four possible oligomers. These results can be used in higher level simulations.

Citing Articles

Molecular Dynamics Simulations of Human Beta-Defensin Type 3 Crossing Different Lipid Bilayers.

Yeasmin R, Brewer A, Fine L, Zhang L ACS Omega. 2021; 6(21):13926-13939.

PMID: 34095684 PMC: 8173616. DOI: 10.1021/acsomega.1c01803.

EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.

Liu W, Liu X, Xu J, Li L, Li Y, Zhang S Acta Pharmacol Sin. 2018; 39(11):1777-1786.

PMID: 30013033 PMC: 6289343. DOI: 10.1038/s41401-018-0069-8.

References

Ganz T . Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003; 3(9):710-20. DOI: 10.1038/nri1180. View

Brogden K . Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol. 2005; 3(3):238-50. DOI: 10.1038/nrmicro1098. View

Voss E, Wehkamp J, Wehkamp K, Stange E, Schroder J, Harder J . NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem. 2005; 281(4):2005-11. DOI: 10.1074/jbc.M511044200. View

Kuwano K, Tanaka N, Shimizu T, Kida Y . Antimicrobial activity of inducible human beta defensin-2 against Mycoplasma pneumoniae. Curr Microbiol. 2006; 52(6):435-8. DOI: 10.1007/s00284-005-0215-7. View

Garzino-Demo A . Chemokines and defensins as HIV suppressive factors: an evolving story. Curr Pharm Des. 2007; 13(2):163-72. DOI: 10.2174/138161207779313696. View

Kanda N, Watanabe S . IL-12, IL-23, and IL-27 enhance human beta-defensin-2 production in human keratinocytes. Eur J Immunol. 2008; 38(5):1287-96. DOI: 10.1002/eji.200738051. View

Gariboldi S, Palazzo M, Zanobbio L, Selleri S, Sommariva M, Sfondrini L . Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4. J Immunol. 2008; 181(3):2103-10. DOI: 10.4049/jimmunol.181.3.2103. View

Krishnakumari V, Rangaraj N, Nagaraj R . Antifungal activities of human beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to Phd3. Antimicrob Agents Chemother. 2008; 53(1):256-60. PMC: 2612179. DOI: 10.1128/AAC.00470-08. View

Droin N, Hendra J, Ducoroy P, Solary E . Human defensins as cancer biomarkers and antitumour molecules. J Proteomics. 2009; 72(6):918-27. DOI: 10.1016/j.jprot.2009.01.002. View

10.

Chandrababu K, Ho B, Yang D . Structure, dynamics, and activity of an all-cysteine mutated human beta defensin-3 peptide analogue. Biochemistry. 2009; 48(26):6052-61. DOI: 10.1021/bi900154f. View

11.

Bai Y, Liu S, Jiang P, Zhou L, Li J, Tang C . Structure-dependent charge density as a determinant of antimicrobial activity of peptide analogues of defensin. Biochemistry. 2009; 48(30):7229-39. DOI: 10.1021/bi900670d. View

12.

Zhuravel E, Shestakova T, Efanova O, Yusefovich Y, Lytvin D, Soldatkina M . Human beta-defensin-2 controls cell cycle in malignant epithelial cells: in vitro study. Exp Oncol. 2011; 33(3):114-20. View

13.

Krishnakumari V, Nagaraj R . Binding of peptides corresponding to the carboxy-terminal region of human-β-defensins-1-3 with model membranes investigated by isothermal titration calorimetry. Biochim Biophys Acta. 2012; 1818(5):1386-94. DOI: 10.1016/j.bbamem.2012.02.016. View

14.

Spudy B, Sonnichsen F, Waetzig G, Grotzinger J, Jung S . Identification of structural traits that increase the antimicrobial activity of a chimeric peptide of human β-defensins 2 and 3. Biochem Biophys Res Commun. 2012; 427(1):207-11. DOI: 10.1016/j.bbrc.2012.09.052. View

15.

Naveed H, Liang J . Weakly stable regions and protein-protein interactions in beta-barrel membrane proteins. Curr Pharm Des. 2013; 20(8):1268-73. PMC: 4127314. DOI: 10.2174/13816128113199990071. View

16.

Jarczak J, Kosciuczuk E, Lisowski P, Strzalkowska N, Jozwik A, Horbanczuk J . Defensins: natural component of human innate immunity. Hum Immunol. 2013; 74(9):1069-79. DOI: 10.1016/j.humimm.2013.05.008. View

17.

Nanda V, Hsieh D, Davis A . Prediction and design of outer membrane protein-protein interactions. Methods Mol Biol. 2013; 1063:183-96. DOI: 10.1007/978-1-62703-583-5_10. View

18.

Wilson S, Wiens M, Smith J . Antiviral mechanisms of human defensins. J Mol Biol. 2013; 425(24):4965-80. PMC: 3842434. DOI: 10.1016/j.jmb.2013.09.038. View

19.

Gerashchenko O, Zhuravel E, Skachkova O, Khranovska N, Pushkarev V, Pogrebnoy P . Involvement of human beta-defensin-2 in regulation of malignant potential of cultured human melanoma cells. Exp Oncol. 2014; 36(1):17-23. View